Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.

Competing Interests: Conflict of interest: J. Corren has received grants from AstraZeneca, Genentech, Optinose, Sanofi, Teva Pharmaceuticals and Vectura, and has received personal fees from AstraZeneca, Genentech and Vectura. C.E. Brightling has received grants and consultancy fees from 4D Pharma, AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals, Roche and Sanofi. L-P. Boulet has received grants and consultancy fees from Amgen, AstraZeneca, Biohaven, Cipla, Covis Pharma, GlaxoSmithKline, Merck, Novartis, Sanofi-Regeneron and Teva Pharmaceuticals. C. Porsbjerg has received grants and consultancy fees from ALK, AstraZeneca, Chiesi, GlaxoSmithKline, Teva Pharmaceuticals, Novartis and Sanofi. M.E. Wechsler is an employee of National Jewish Health and has received consultancy, advisory or speaking fees from Amgen, AstraZeneca, Ayala Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset Therapeutics, Novartis, Pylaxis, Pulmatrix, Rapt Therapeutics, Regeneron Pharmaceuticals, resTORbio, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Teva Pharmaceuticals and Upstream Bio. A. Menzies-Gow is an employee of AstraZeneca and may own stock or stock options in AstraZeneca, has attended advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals, has received speaker fees from AstraZeneca, Novartis, Roche and Teva Pharmaceuticals, has participated in research with AstraZeneca, for which his institution has been remunerated, has attended international conferences with Teva Pharmaceuticals, and has consultancy agreements with AstraZeneca and Sanofi. C.S. Ambrose, B. Cook, N. Martin and J. Spahn are employees of AstraZeneca and may own stock or stock options in AstraZeneca. J-P. Llanos is an employee of Amgen and owns stock in Amgen.